Y. Mehmood, H. Shahid, Aysha Tariq, Syeda Omama Ali
Common inflammatory airway disorders, such as seasonal and perennial allergic rhinitis, acute sinusitis, and nasal polyposis, can have a significant impact on patient health and quality of life. Intranasal corticosteroids are recommended as part of treatment plans for each of these illnesses because they reduce inflammation and thus symptoms. In order to compare the efficacy and safety of a new nano formulation of mometasone furoate nano-nasal spray (MF-NNS) with a commercially available nasal spray called mometasone furoate nasal spray (MFNS) for the treatment of allergic rhinitis, 20 rhinitis patients were enrolled in this randomized controlled trial (10 to 50 years). Patients were given 50 mcg MF-NNS doses in the morning and evening. This regimen was administered as a nasal spray for a 3-week efficacy and safety phase. The primary endpoints changed from baseline in the subjects’ congestion as determined by the physicians’ assessment of allergic rhinitis. Analysis of variance was used to evaluate all efficacy end points. More clinical trials have shown that MF-NNS reduces both objective and subjective markers of inflammation in adults, adolescents, and children.
{"title":"Efficacy and safety of a new mometasone furoate nasal spray formulation in patients with acute rhinosinusitis: a randomized clinical trial","authors":"Y. Mehmood, H. Shahid, Aysha Tariq, Syeda Omama Ali","doi":"10.4081/itjm.2022.1533","DOIUrl":"https://doi.org/10.4081/itjm.2022.1533","url":null,"abstract":"Common inflammatory airway disorders, such as seasonal and perennial allergic rhinitis, acute sinusitis, and nasal polyposis, can have a significant impact on patient health and quality of life. Intranasal corticosteroids are recommended as part of treatment plans for each of these illnesses because they reduce inflammation and thus symptoms. In order to compare the efficacy and safety of a new nano formulation of mometasone furoate nano-nasal spray (MF-NNS) with a commercially available nasal spray called mometasone furoate nasal spray (MFNS) for the treatment of allergic rhinitis, 20 rhinitis patients were enrolled in this randomized controlled trial (10 to 50 years). Patients were given 50 mcg MF-NNS doses in the morning and evening. This regimen was administered as a nasal spray for a 3-week efficacy and safety phase. The primary endpoints changed from baseline in the subjects’ congestion as determined by the physicians’ assessment of allergic rhinitis. Analysis of variance was used to evaluate all efficacy end points. More clinical trials have shown that MF-NNS reduces both objective and subjective markers of inflammation in adults, adolescents, and children.","PeriodicalId":43715,"journal":{"name":"Italian Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48633242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Manfellotto, Monica Cortinovis, N. Perico, G. Remuzzi
Chronic kidney diseases have a significant impact on morbidity and mortality worldwide. Low birth weight, fetal growth restriction and prematurity are indicators of fetal growth and development disorders associated with a congenital reduction in nephron number, which predisposes to an increased risk for chronic kidney disease. On an individual basis, a small nephron number at birth is not always enough to determine the onset of chronic kidney disease, but it decreases the ability of the kidneys to resist any insults to renal tissue that may occur later in life, such as exposure to nephrotoxic drugs or episodes of acute kidney injury. The high incidence of low birth weight and preterm birth globally suggests that, at the population level, the impact of alterations in fetal development on the subsequent onset of chronic kidney disease could be significant. The implementation of strategies aimed at reducing the incidence of prematurity, fetal growth restriction, as well as other conditions that lead to low birth weight and a reduced nephron number at birth, provides an opportunity to prevent the development of chronic kidney disease in adulthood. For these purposes the coordinated intervention of several specialists, including obstetricians, gynecologists, neonatologists, nephrologists, and family doctors, is necessary. Such strategies can be particularly useful in resource-poor countries, which are simultaneously burdened by maternal, fetal and child malnutrition; poor health; epidemics caused by communicable diseases; and little access to screening and primary care.
{"title":"Low birth weight, nephron number and chronic kidney disease","authors":"D. Manfellotto, Monica Cortinovis, N. Perico, G. Remuzzi","doi":"10.4081/itjm.2022.1538","DOIUrl":"https://doi.org/10.4081/itjm.2022.1538","url":null,"abstract":"Chronic kidney diseases have a significant impact on morbidity and mortality worldwide. Low birth weight, fetal growth restriction and prematurity are indicators of fetal growth and development disorders associated with a congenital reduction in nephron number, which predisposes to an increased risk for chronic kidney disease. On an individual basis, a small nephron number at birth is not always enough to determine the onset of chronic kidney disease, but it decreases the ability of the kidneys to resist any insults to renal tissue that may occur later in life, such as exposure to nephrotoxic drugs or episodes of acute kidney injury. The high incidence of low birth weight and preterm birth globally suggests that, at the population level, the impact of alterations in fetal development on the subsequent onset of chronic kidney disease could be significant. The implementation of strategies aimed at reducing the incidence of prematurity, fetal growth restriction, as well as other conditions that lead to low birth weight and a reduced nephron number at birth, provides an opportunity to prevent the development of chronic kidney disease in adulthood. For these purposes the coordinated intervention of several specialists, including obstetricians, gynecologists, neonatologists, nephrologists, and family doctors, is necessary. Such strategies can be particularly useful in resource-poor countries, which are simultaneously burdened by maternal, fetal and child malnutrition; poor health; epidemics caused by communicable diseases; and little access to screening and primary care.","PeriodicalId":43715,"journal":{"name":"Italian Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44371838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Montagnani, S. Frasson, G. Gussoni, F. Dentali, A. Fontanella, D. Manfellotto
In Italy, Internal Medicine Units hospitalize approximately 1,300,000 patients, often elderly and comorbid. The prevalent diagnoses are respiratory diseases, heart failure, or pneumonia. As a matter of fact, anemia is probably underestimated in the compilation of the official discharge forms (SDO) according to ICD-9 diagnostic codes. We promoted a survey among the Members the Italian Scientific Society of Internal Medicine (FADOI) with the aim to investigate the prevalence of anemia and iron deficiency, over than certain aspects related to the therapeutic management of patients with anemia. Furthermore, we performed a review summarizing current evidence for iron intravenous therapy in these patients. According to the survey, anemia is present in around half of the patients hospitalized in Internal Medicine, and about a quarter of them shows iron metabolism alterations. In the evaluation of iron metabolism, the dosage of ferritin is the most requested exam, whereas transferrin saturation is less considered. By focusing on some categories of patients, the awareness of the usefulness of intravenous iron therapy in patients with heart failure seems to be sufficiently common (76% of physicians), while it seems lower (60%) in the management of patients with chronic kidney disease (CKD) and anemia. Finally, more than 75% of the physicians answered that, in their hospital, there are few outpatients’ offices or diagnostic pathways dedicated to patients with anemia. Anemia due to absolute or functional iron deficiency is particularly prevalent in Internal Medicine inpatients. For this reason, an accurate evaluation of iron profile and an adequate iron therapy is mandatory in these patients. Recent studies show that, in patients with heart failure, intravenous iron therapy is an effective way of improving patients’ health, regardless of the presence of anemia. Similarly, iron therapy results fundamental to optimize erythropoiesis-stimulating agent efficacy in patients with chronic renal failure. In the next future, other therapeutic aspects of intravenous iron therapy will be probably clarified by several interesting ongoing studies focused on these patients.
{"title":"Anemia and iron in internal medicine: an Italian survey and a review on iron intravenous therapy in medical patients","authors":"A. Montagnani, S. Frasson, G. Gussoni, F. Dentali, A. Fontanella, D. Manfellotto","doi":"10.4081/itjm.2022.1532","DOIUrl":"https://doi.org/10.4081/itjm.2022.1532","url":null,"abstract":"In Italy, Internal Medicine Units hospitalize approximately 1,300,000 patients, often elderly and comorbid. The prevalent diagnoses are respiratory diseases, heart failure, or pneumonia. As a matter of fact, anemia is probably underestimated in the compilation of the official discharge forms (SDO) according to ICD-9 diagnostic codes. We promoted a survey among the Members the Italian Scientific Society of Internal Medicine (FADOI) with the aim to investigate the prevalence of anemia and iron deficiency, over than certain aspects related to the therapeutic management of patients with anemia. Furthermore, we performed a review summarizing current evidence for iron intravenous therapy in these patients. According to the survey, anemia is present in around half of the patients hospitalized in Internal Medicine, and about a quarter of them shows iron metabolism alterations. In the evaluation of iron metabolism, the dosage of ferritin is the most requested exam, whereas transferrin saturation is less considered. By focusing on some categories of patients, the awareness of the usefulness of intravenous iron therapy in patients with heart failure seems to be sufficiently common (76% of physicians), while it seems lower (60%) in the management of patients with chronic kidney disease (CKD) and anemia. Finally, more than 75% of the physicians answered that, in their hospital, there are few outpatients’ offices or diagnostic pathways dedicated to patients with anemia. Anemia due to absolute or functional iron deficiency is particularly prevalent in Internal Medicine inpatients. For this reason, an accurate evaluation of iron profile and an adequate iron therapy is mandatory in these patients. Recent studies show that, in patients with heart failure, intravenous iron therapy is an effective way of improving patients’ health, regardless of the presence of anemia. Similarly, iron therapy results fundamental to optimize erythropoiesis-stimulating agent efficacy in patients with chronic renal failure. In the next future, other therapeutic aspects of intravenous iron therapy will be probably clarified by several interesting ongoing studies focused on these patients.","PeriodicalId":43715,"journal":{"name":"Italian Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41960633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
IntroduzioneDario Manfellotto, Francesco Dentali, Andrea Fontanella Materiali e MetodiDario Manfellotto, Francesco Dentali, Andrea Fontanella Gestione clinica del paziente complesso con patologie cardiovascolari e comorbilitàGiuseppe Campagna, Claudia Ferrigno, Franco Mastroianni Gestione clinica del paziente complesso con diabete e comorbilitàAda Maffettone, Ernesto De Menis, Maria Serena Fiore Cura e comunicazione: l’esperienza nella pandemia e le prospettive futureLuigi Magnani, Lara Bellardita, Salvatore Lenti Gestione a distanza del paziente complesso: la medicina digitaleFilippo Pieralli, Flavio Tangianu, Maria Gabriella Coppola Governance per la Medicina InternaAndrea Montagnani, Roberta Re, Ilario Stefani Considerazioni conclusiveDario Manfellotto, Francesco Dentali, Andrea Fontanella
{"title":"Progetto FADOI “EUCLIDE”. Clinica, comunicazione, telemedicina e governance: le esperienze da COVID-19 per il futuro della Medicina Interna","authors":"D. Manfellotto, Francesco Dentali, A. Fontanella","doi":"10.4081/itjm.q.2022.2","DOIUrl":"https://doi.org/10.4081/itjm.q.2022.2","url":null,"abstract":"\u0000IntroduzioneDario Manfellotto, Francesco Dentali, Andrea Fontanella\u0000Materiali e MetodiDario Manfellotto, Francesco Dentali, Andrea Fontanella\u0000Gestione clinica del paziente complesso con patologie cardiovascolari e comorbilitàGiuseppe Campagna, Claudia Ferrigno, Franco Mastroianni\u0000Gestione clinica del paziente complesso con diabete e comorbilitàAda Maffettone, Ernesto De Menis, Maria Serena Fiore\u0000Cura e comunicazione: l’esperienza nella pandemia e le prospettive futureLuigi Magnani, Lara Bellardita, Salvatore Lenti\u0000Gestione a distanza del paziente complesso: la medicina digitaleFilippo Pieralli, Flavio Tangianu, Maria Gabriella Coppola\u0000Governance per la Medicina InternaAndrea Montagnani, Roberta Re, Ilario Stefani\u0000Considerazioni conclusiveDario Manfellotto, Francesco Dentali, Andrea Fontanella","PeriodicalId":43715,"journal":{"name":"Italian Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43653229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. Gnerre, Mercedes Pasquali, Giuseppe Aiosa, A. Daniele, Stefania Crivellari, Marinella Bertolotti, Christian Salerno, A. Di Dio, G. Pacileo, A. Maconi, Sara Marchisio
Non disponibile
不可用
{"title":"Esiti dei pazienti COVID-19 positivi ricoverati durante la quarta ondata pandemica in relazione alle caratteristiche cliniche e allo stato vaccinale","authors":"P. Gnerre, Mercedes Pasquali, Giuseppe Aiosa, A. Daniele, Stefania Crivellari, Marinella Bertolotti, Christian Salerno, A. Di Dio, G. Pacileo, A. Maconi, Sara Marchisio","doi":"10.4081/itjm.q.2022.3","DOIUrl":"https://doi.org/10.4081/itjm.q.2022.3","url":null,"abstract":"Non disponibile","PeriodicalId":43715,"journal":{"name":"Italian Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47528467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract book of the XXVII Congresso Nazionale della Società Scientifica FADOI, 21-23 maggio 2022.
FADOI科学学会第二十七届全国代表大会摘要，2022年5月21日至23日。
{"title":"Abstract book of the XXVII Congresso Nazionale della Società Scientifica FADOI, 21-23 maggio 2022","authors":"D. Manfellotto","doi":"10.4081/itjm.2022.s1","DOIUrl":"https://doi.org/10.4081/itjm.2022.s1","url":null,"abstract":"Abstract book of the XXVII Congresso Nazionale della Società Scientifica FADOI, 21-23 maggio 2022.","PeriodicalId":43715,"journal":{"name":"Italian Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44540607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Francesco Dentali, G. Campagna, Maurizio Cavalleri, Fernando Gallucci, Filippo Pieralli
Nuova classificazione dello scompenso cardiaco: ridenominazione di Heart failure with mid-range ejection fraction in Heart failure with mildly reduced ejection fraction (HFmrEF), con raccomandazioni terapeutiche più precise in questa fascia di pazienti Il nuovo algoritmo per il trattamento dello scompenso cardiaco a frazione di eiezione ridotta: Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure Ottimizzazione della terapia: l’ospedalizzazione come opportunità. Impiego precoce di sacubitril/valsartan nel paziente ospedalizzato, stabilizzato. Effetti sulla riduzione della mortalità e delle re-ospedalizzazioni. Effetti sul rimodellamento cardiaco. Effetti sulla QoL Sicurezza dell’uso di sacubitril/valsartan anche in presenza di comorbidità e gestione dell’ipotensione Intervento di ottimizzazione della terapia anche nel paziente con scompenso cardiaco cronico ricoverato per altra patologia acuta Terapia delle comorbidità - non cardiovascolari: diabete, iperkaliemia, carenza di ferro e cancro Terapia non farmacologica ed educazione/formazione del paziente e del caregiver Gestione post-ricovero dello scompenso cardiaco: l’ambulatorio divisionale e la rete territoriale
{"title":"Considerazioni condivise alla luce delle recenti novità nell’ambito dello scompenso cardiaco: ottimizzazione della gestione del paziente con scompenso cardiaco in medicina interna - Dal ricovero al follow-up","authors":"Francesco Dentali, G. Campagna, Maurizio Cavalleri, Fernando Gallucci, Filippo Pieralli","doi":"10.4081/itjm.q.2021.5","DOIUrl":"https://doi.org/10.4081/itjm.q.2021.5","url":null,"abstract":"\u0000Nuova classificazione dello scompenso cardiaco: ridenominazione di Heart failure with mid-range ejection fraction in Heart failure with mildly reduced ejection fraction (HFmrEF), con raccomandazioni terapeutiche più precise in questa fascia di pazienti \u0000Il nuovo algoritmo per il trattamento dello scompenso cardiaco a frazione di eiezione ridotta: Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure \u0000Ottimizzazione della terapia: l’ospedalizzazione come opportunità. Impiego precoce di sacubitril/valsartan nel paziente ospedalizzato, stabilizzato. Effetti sulla riduzione della mortalità e delle re-ospedalizzazioni. Effetti sul rimodellamento cardiaco. Effetti sulla QoL \u0000Sicurezza dell’uso di sacubitril/valsartan anche in presenza di comorbidità e gestione dell’ipotensione \u0000Intervento di ottimizzazione della terapia anche nel paziente con scompenso cardiaco cronico ricoverato per altra patologia acuta \u0000Terapia delle comorbidità - non cardiovascolari: diabete, iperkaliemia, carenza di ferro e cancro \u0000Terapia non farmacologica ed educazione/formazione del paziente e del caregiver \u0000Gestione post-ricovero dello scompenso cardiaco: l’ambulatorio divisionale e la rete territoriale","PeriodicalId":43715,"journal":{"name":"Italian Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48251326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gravidanza e patologie autoimmuniC. Politi, V. Donvito, A. Tincani La contraccezione e la terapia estroprogestinica nelle donne con malattie autoimmuniM. Montesano, R. Picilli, G. Nova, M. Vignali Gravidanza e monitoraggio fetale in pazienti con malattie reumatiche autoimmuniI. Cetin, R. Milazzo, L. Basili Lupus eritematoso sistemico e gravidanzaM. Larosa, A. Doria Artrite reumatoideV.L. Ramoni Sindrome da anticorpi anti-fosfolipidi in gravidanza e puerperioM.C. Gerardi, C. Nalli, D. Lini, A. Tincani Gravidanza e sclerosi sistemica (sclerodermia)A. Brucato, M. Nivuori, A. Mazzone Anticorpi anti-Ro/SSA, sindrome di Sjögren, lupus neonatale e blocco cardiaco congenitoC. Picchi, E. Tombetti, A.L. Brucato Patologie della tiroide in gravidanzaS. De Carolis, E. Barbagelata, I. Ambrosino, S. Tabacco Gestione della gravidanza nelle donne con malattia di Behçet e vasculitiM. Gerosa, M. Cornalba, A. Sinelli, R. Cimaz, R. Caporali Sclerosi multiplaA. Protti, E.L. Susani, L. Saraceno, M.R. Marazzi, E.C. Agostoni Malattie autoinfiammatorie ereditarie e gravidanzaL. Obici Pericardite in gravidanzaE. Barbagelata, I. Ambrosino, E. Bernero, A. Brucato Fisiologia del rene in gravidanzaT. Ciarambino, F. Saladini, D. Manfellotto Terapia con farmaci antireumatici in corso di gravidanza e allattamentoM.C. Gerardi, D. Lini, L. Andreoli Il ruolo delle analisi di laboratorio nella gravidanza delle donne con malattie immunoreumatologicheF. Bartoli, C.B. Chighizola Gravidanza e malattie autoimmuni: il bambinoM. Romano, R. Cimaz Fecondazione medicalmente assistita nelle malattie autoimmuni sistemicheS. Truglia, S. Mancuso, F. Conti Il punto di vista delle pazienti: la ricerca che accarezzaI. Galetti, S. Ostuzzi
怀孕和自身免疫性疾病。A.对患有自身免疫性疾病的妇女进行节育和外延治疗。Montesano, R. Picilli, G. Nova, M. Vignali在风湿性自身免疫性疾病患者中怀孕和胎儿监测。Cetin, R. Milazzo, L. Basili全身红斑狼疮和怀孕。拉罗萨，A.多利亚关节炎风湿性关节炎。怀孕和产期抗磷脂抗体综合征。Gerardi, C. Nalli, D. leny, A.妊娠和全身硬化症(硬化症)Brucato, M . Nivuori,马佐尼anti-Ro / SSA抗体,Sjö综合症是,新生儿狼疮和心率congenitoC封锁。啄木鸟，E. tom贝蒂，a.l.。E .始于,De Carolis。女性怀孕的Ambrosino, S .烟草管理与嗯çet和vasculitiM的疾病。Gerosa, M. Cornalba, A. Sinelli, R. Cimaz，Protti, e.l. Susani, L. Saraceno, m.r. Marazzi, e.c. Agostoni遗传性自燃疾病和怀孕。怀孕的心包炎。Barbagelata, I. ambroosino, E. Bernero, A.在怀孕期间烧伤的肾脏生理。ciambino, F. salati, D. Manfellotto妊娠和哺乳抗风湿性药物治疗。Gerardi, D. Lini, L. Andreoli，实验室分析在免疫病理妇女怀孕中的作用。怀孕和自身免疫性疾病:婴儿。罗马诺，R. Cimaz，在自体免疫系统疾病中接受药物治疗。特鲁格利亚，S.曼库索，F.从病人的角度来看:我所做的研究。Galetti, S. Ostuzzi
{"title":"Gravidanza e malattie autoimmuni","authors":"Guest Editor: Paola Gnerre","doi":"10.4081/itjm.q.2021.4","DOIUrl":"https://doi.org/10.4081/itjm.q.2021.4","url":null,"abstract":"\u0000Gravidanza e patologie autoimmuniC. Politi, V. Donvito, A. Tincani \u0000La contraccezione e la terapia estroprogestinica nelle donne con malattie autoimmuniM. Montesano, R. Picilli, G. Nova, M. Vignali \u0000Gravidanza e monitoraggio fetale in pazienti con malattie reumatiche autoimmuniI. Cetin, R. Milazzo, L. Basili \u0000Lupus eritematoso sistemico e gravidanzaM. Larosa, A. Doria \u0000Artrite reumatoideV.L. Ramoni \u0000Sindrome da anticorpi anti-fosfolipidi in gravidanza e puerperioM.C. Gerardi, C. Nalli, D. Lini, A. Tincani \u0000Gravidanza e sclerosi sistemica (sclerodermia)A. Brucato, M. Nivuori, A. Mazzone \u0000Anticorpi anti-Ro/SSA, sindrome di Sjögren, lupus neonatale e blocco cardiaco congenitoC. Picchi, E. Tombetti, A.L. Brucato \u0000Patologie della tiroide in gravidanzaS. De Carolis, E. Barbagelata, I. Ambrosino, S. Tabacco \u0000Gestione della gravidanza nelle donne con malattia di Behçet e vasculitiM. Gerosa, M. Cornalba, A. Sinelli, R. Cimaz, R. Caporali \u0000Sclerosi multiplaA. Protti, E.L. Susani, L. Saraceno, M.R. Marazzi, E.C. Agostoni \u0000Malattie autoinfiammatorie ereditarie e gravidanzaL. Obici \u0000Pericardite in gravidanzaE. Barbagelata, I. Ambrosino, E. Bernero, A. Brucato \u0000Fisiologia del rene in gravidanzaT. Ciarambino, F. Saladini, D. Manfellotto \u0000Terapia con farmaci antireumatici in corso di gravidanza e allattamentoM.C. Gerardi, D. Lini, L. Andreoli \u0000Il ruolo delle analisi di laboratorio nella gravidanza delle donne con malattie immunoreumatologicheF. Bartoli, C.B. Chighizola \u0000Gravidanza e malattie autoimmuni: il bambinoM. Romano, R. Cimaz \u0000Fecondazione medicalmente assistita nelle malattie autoimmuni sistemicheS. Truglia, S. Mancuso, F. Conti \u0000Il punto di vista delle pazienti: la ricerca che accarezzaI. Galetti, S. Ostuzzi","PeriodicalId":43715,"journal":{"name":"Italian Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41682361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Il presente documento è stato redatto nell’ambito del progetto di sensibilizzazione sul tema di Fondazione Onda.
本文件是作为关于翁达基金会主题的宣传项目的一部分编写的。
{"title":"Position Paper FADOI – SIGG","authors":"A. Fontanella, D. Manfellotto, F. Landi","doi":"10.4081/itjm.q.2021.s1","DOIUrl":"https://doi.org/10.4081/itjm.q.2021.s1","url":null,"abstract":"Il presente documento è stato redatto nell’ambito del progetto di sensibilizzazione sul tema di Fondazione Onda.","PeriodicalId":43715,"journal":{"name":"Italian Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44459977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Diabetes is a chronic metabolic disorder that disturbs the quality of life (QOL) of patients. Therefore, evaluation of diabetes- related QOL could be a key outcome measure for its management. This study assessed the QOL in type 2 diabetes mellitus (T2DM) patients using the World Health Organization (WHO) quality of life (QOL)˗BREF questionnaire and disease-specific appraisal of diabetes scale (ADS). In this cross-sectional study, 520 T2DM patients were included. Patients’ demographic data, clinical information was collected through interviews, and the WHOQOL-BREF instrument and ADS were used for the QOL of patients. Statistical analysis was performed by using R software (Version 3.6.0). The mean ADS scores were lower in controlled diabetic subjects (18.50±3.08) and higher in uncontrolled diabetic subjects (19.29±2.73) (P<0.05). For WHOQOL-BREF, the mean scores for all the domains (overall general health, physical, psychological, social, and environmental) were significantly higher in controlled diabetic subjects (P<0.001). In addition, the age, duration of diabetes, associated comorbidities, treatment, and HbA1c level of patients showed a highly significant correlation with WHOQOL-BREF (P<0.001). Diabetic patients had poor-to-average QOL. Therefore, public health measures and education of diabetic patients are essential to create more awareness for improving the QOL of T2DM.
{"title":"Assessment of quality of life in type 2 diabetes mellitus patients using World Health Organization quality of life-BREF questionnaire and appraisal of diabetes scale - a cross-sectional study","authors":"Supriya Patil, Yamini Patil, S. Patil","doi":"10.4081/itjm.2021.1444","DOIUrl":"https://doi.org/10.4081/itjm.2021.1444","url":null,"abstract":"Diabetes is a chronic metabolic disorder that disturbs the quality of life (QOL) of patients. Therefore, evaluation of diabetes- related QOL could be a key outcome measure for its management. This study assessed the QOL in type 2 diabetes mellitus (T2DM) patients using the World Health Organization (WHO) quality of life (QOL)˗BREF questionnaire and disease-specific appraisal of diabetes scale (ADS). In this cross-sectional study, 520 T2DM patients were included. Patients’ demographic data, clinical information was collected through interviews, and the WHOQOL-BREF instrument and ADS were used for the QOL of patients. Statistical analysis was performed by using R software (Version 3.6.0). The mean ADS scores were lower in controlled diabetic subjects (18.50±3.08) and higher in uncontrolled diabetic subjects (19.29±2.73) (P<0.05). For WHOQOL-BREF, the mean scores for all the domains (overall general health, physical, psychological, social, and environmental) were significantly higher in controlled diabetic subjects (P<0.001). In addition, the age, duration of diabetes, associated comorbidities, treatment, and HbA1c level of patients showed a highly significant correlation with WHOQOL-BREF (P<0.001). Diabetic patients had poor-to-average QOL. Therefore, public health measures and education of diabetic patients are essential to create more awareness for improving the QOL of T2DM.","PeriodicalId":43715,"journal":{"name":"Italian Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44066725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：